Status:
COMPLETED
Intravenous Allopurinol in Heart Failure
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Congestive Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.
Detailed Description
Xanthine oxidase have been reported to improve mechano-energetic coupling in failing hearts. The investigators developed a means to directly measure creatine kinase flux, the major energy reserve of t...
Eligibility Criteria
Inclusion
- Age \> 18 years
- The patient is willing and able to provide informed consent
- Clinical diagnosis of chronic heart failure
- Ejection fraction (EF) \< 40% by echocardiography, nuclear multigated acquisition (MUGA) or cath ventriculography
- No significant coronary disease at cardiac catheterization
- New York Heart Association (NYHA) Class I-IV symptoms
- Clinical stabilization for two weeks if following recent congestive heart failure (CHF) decompensation.
Exclusion
- Metallic implant prohibiting magnetic resonance (MR) evaluation
- Inability to lie flat for MR study
- Administration of additional investigational drugs
- Calculated creatinine clearance \< 50 mL/min
- Allergy to allopurinol
- Current gout flare
- Currently taking oral allopurinol
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00181155
Start Date
November 1 2004
End Date
December 1 2010
Last Update
May 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287